Coronavirus Update: Pfizer/BioNTech Announce Positive Early Booster Data
The announcement comes amid signs of lagging bivalent booster uptake despite the possibility of a fall and winter surge. Novavax announced data from its combination coronavirus-influenza vaccine, but doubts remain as its approach’s competitiveness against mRNA vaccines. Moderna and Pfizer received EUAs for their bivalent vaccines in young children.
You may also be interested in...
"I still remember how I screamed 'oh my god, it's just unbelievable,'" worldwide president R&D Mikael Dolsten told Scrip, reflecting on the moment he heard the first COVID-19 vaccine results.
Pfizer/BioNtech’s and Moderna’s updated bivalent Omicron booster doses will be available in coming days. Pfizer/BioNtech has an ongoing study in individuals 12 and older and are preparing EUA application for those 6 months and older. Moderna completed enrollment of 512 participants in a Phase 2/3 trial.
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.